• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP
Click for more information
2.33% 21.0¢

CYNATA THERAPEUTICS LIMITED - Charts / Financials

Market Cap $37.91M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

refresh Created with Sketch. REFRESH
Last update - 15.42pm 23/08/2024 (20 minute delay) ?
Day
Open 21.0¢   Day High 21.0¢   Day Low 20.5¢
Daily Volume 53686
Bids   Sellers
Number Price Volume   Number Price Volume
1 20.5¢ 7339   2 22.5¢ 32225

Directors & Senior Management

Dr. Kilian Kelly Chief Executive Officer, Managing Director, Director
Dr. Suzanne Lipe Vice President - Partner Engagement
Dr. Jolanta Airey Chief Medical Officer
Dr. Mathias Kroll Chief Business Officer
Mr. Peter Gordon Webse Company Secretary
Dr. Geoffrey E. D. Brooke Independent Non-Executive Chairman of the Board
Ms. Janine Rolfe Director
Dr. Darryl Maher Non-Executive Independent Director
Dr. Paul K. Wotton Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
21.0¢ 		Change
-0.005(2.33%) 		Mkt cap ! $37.91M
Open High Low Value Volume
21.0¢ 21.0¢ 20.5¢ $11.26K 53.68K

Buyers (Bids)

No. Vol. Price($)
1 7339 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 32225 2
View Market Depth
Last trade - 15.39pm 23/08/2024 (20 minute delay) ?
Last
21.5¢ 		  Change
-0.005 ( 2.27 %)
Open High Low Volume
20.0¢ 21.5¢ 20.0¢ 2671
Last updated 15.42pm 23/08/2024 ?

Top Stories

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

Given the recent fall in iron ore prices below the $100 mark, now might be the time to buy into specialised stocks in the materials sector.
Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign Strategic Energy Resources is 4 holes into a 40-hole RC drill campaign at its Achilles 1 copper-gold target in the Cobar Basin of NSW.
The business of sport: Warren Tredrea's take on this week's news Former Port Adelaide AFL star – turned media personality – Warren Tredrea and co-host Jack Hudson explore money in sport.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.